№ files_lp_4_process_3_087872
File format: docx Character count: 468 File size: 366 KB
Distribution of immune features of M2 macrophages, TGF-β, plasma cells, and memory activated CD4+ T cells by BRAF V600E mutation as presented in a scientific figure.
Year: Not specified
Region / City: Not specified
Subject: Immune features, BRAF V600E mutation
Document type: Scientific figure
Author: Not specified
Target audience: Researchers in immunology
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Addendum to the submission for Dabrafenib and Trametinib for the treatment of paediatric low-grade and high-grade glioma with BRAF V600E mutation
Year: 2023
Region / City: Australia
Theme: Paediatric Oncology, Pharmacology
Document Type: Medical Submission
Organization / Institution: Novartis Pharmaceuticals Australia Pty Limited
Author: Novartis Pharmaceuticals Australia Pty Limited
Target Audience: Medical practitioners, oncologists, pharmacists, healthcare providers
Period of Validity: Not specified
Approval Date: 6 December 2023
Date of Amendments: Not specified
Addendum to the submission for Dabrafenib and Trametinib for the treatment of paediatric low-grade and high-grade glioma with BRAF V600E mutation
Year: 2023
Region / City: Australia
Theme: Paediatric Oncology, Pharmacology
Document Type: Medical Submission
Organization / Institution: Novartis Pharmaceuticals Australia Pty Limited
Author: Novartis Pharmaceuticals Australia Pty Limited
Target Audience: Medical practitioners, oncologists, pharmacists, healthcare providers
Period of Validity: Not specified
Approval Date: 6 December 2023
Date of Amendments: Not specified
Melanoma specimens analyzed for PD-L1 expression, BRAF mutation, and inflammatory infiltrate
Year: 2026
Region/Location: Not specified
Subject: Melanoma research
Document type: Supplementary data tables
Institution: Research laboratory / academic study
Author: Not specified
Sample size: NEVI (14), Primary Malignant Melanoma (23), Metastatic Melanoma (15)
Methods: Immunohistochemistry for PD-L1, BRAF codon 600 genotyping, inflammatory scoring
Cell lines: Human melanoma cultured cells
Treatment: IFN-gamma induction
Data metrics: %PD-L1 expression, inflammation score, ∆MFI for PD-L1 and MHC I
Context: Archival melanoma tissue samples and cultured melanoma cell lines analyzed for PD-L1 expression, BRAF mutation status, and immune response markers in experimental study
Topics: V600E TGF- BRAF